Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543065 | 0.84 | MEN1 (0.48) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL542561 | 0.79 | LMNA (0.53) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL20134878 | 0.79 | LMNA (0.53) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL4385865 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL542817 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL10131744 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL6135313 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL204119 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL17054772 | 0.78 | MEN1 (0.55) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL17570773 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-1997006153-A1 | 4-ALKYL-1,3-OXA(THIA)ZOLINE DERIVATIVES, THEIR PREPARATION AND USE FOR CONTROLLING ANIMAL PESTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | MEN1 3926/4885KMT2A 1414/4885LMNA 1674/4885 |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | MEN1 3823/4885KMT2A 2383/4885LMNA 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.